Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Recurrence 1Peritoneal Neoplasms 1Papillomavirus Infections 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms, Glandular and Epithelial 1Genital Neoplasms, Female 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma in Situ 1Abdominal Neoplasms 1

Interventions

fludarabine phosphate 1fludarabine 1cemiplimab 1aldesleukin 1Sampling Studies 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Meperidine 1Magnetic Resonance Imaging 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Granisetron 1Electrocardiography 1Droperidol 1Doxylamine 1Diphenoxylate 1Diphenhydramine 1Cyclophosphamide 1Codeine 1Cell Count 1Blood Specimen Collection 1Biopsy 1Atropine 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma in Situ × Cell Count × Gynecologic × Clear all
NCT02858310 2026-03-09

E7 TCR T Cells for Human Papillomavirus-Associated Cancers

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
224 enrolled 15 charts
Gynecologic

Carcinoma in Situ, Uterine Cervical Dysplasia, Vulvar Diseases, Vulvar Neoplasms, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡